Cargando…

Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein

Precision medicine is defined by the administration of drugs based on the tumor’s particular genetic characteristics. It is developing quickly in the field of cancer therapy. For example, KRAS, NRAS and BRAF genetic testing demonstrates its efficiency for precision medicine in colorectal cancer (CRC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghiringhelli, Francois, Richard, Corentin, Chevrier, Sandy, Végran, Frédérique, Boidot, Romain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192280/ https://www.ncbi.nlm.nih.gov/pubmed/28082821 http://dx.doi.org/10.3748/wjg.v22.i48.10680

Ejemplares similares

Transcriptome analysis of T(H)2 CD4(+) T cells differentiated from wild-type and NLRP3KO mice
por: Bruchard, Mélanie, et al.
Publicado: (2015)

IRF8-dependent molecular complexes control the Th9 transcriptional program
por: Humblin, Etienne, et al.
Publicado: (2017)

Only Missense Mutations Affecting the DNA Binding Domain of P53 Influence Outcomes in Patients with Breast Carcinoma
por: Végran, Frédérique, et al.
Publicado: (2013)

EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma
por: Richard, Corentin, et al.
Publicado: (2018)

Survivin-3B promotes chemoresistance and immune escape by inhibiting caspase-8 and -6 in cancer cells
por: Végran, Frédérique, et al.
Publicado: (2013)

Alternative Splicing in Cancer and Immune Cells
por: Bernard, Antoine, et al.
Publicado: (2022)

Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy
por: Schmitt, Esther, et al.
Publicado: (2015)

An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers
por: Chevrier, Sandy, et al.
Publicado: (2021)

Transient Response of Olaparib on Pulmonary Artery Sarcoma Harboring Multiple Homologous Recombinant Repair Gene Alterations
por: Wu, Chiao-En, et al.
Publicado: (2021)

A Short Caspase-3 Isoform Inhibits Chemotherapy-Induced Apoptosis by Blocking Apoptosome Assembly
por: Végran, Frédérique, et al.
Publicado: (2011)

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment
por: Fumet, Jean-David, et al.
Publicado: (2020)

Use of dedicated gene panel sequencing using next generation sequencing to improve the personalized care of lung cancer
por: Kaderbhai, Coureche Guillaume, et al.
Publicado: (2016)

Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis
por: Matsubara, Nobuaki, et al.
Publicado: (2022)

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
por: Dosset, Magalie, et al.
Publicado: (2018)

Socs3 induction by PPARγ restrains cancer-promoting inflammation
por: Végran, Frédérique, et al.
Publicado: (2013)

STAT3 activation: A key factor in tumor immunoescape
por: Rébé, Cédric, et al.
Publicado: (2013)

Regulation of T cell antitumor immune response by tumor induced metabolic stress
por: Chalmin, Fanny, et al.
Publicado: (2018)

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer
por: Lecuelle, Julie, et al.
Publicado: (2022)

Association of Anti-EGFR Antibody and MEK Inhibitor in Gynecological Cancer Harboring RAS Mutation: A Case Series
por: Niogret, Julie, et al.
Publicado: (2022)

PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy
por: Tharin, Zoé, et al.
Publicado: (2023)

Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type
por: Dalens, Lorraine, et al.
Publicado: (2023)

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer
por: Galland, Loïck, et al.
Publicado: (2023)

A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations
por: Thavaneswaran, Subotheni, et al.
Publicado: (2023)

T(H)9 cells in anti-tumor immunity
por: Rivera Vargas, Thaiz, et al.
Publicado: (2016)

Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
por: Christinat, Yann, et al.
Publicado: (2023)

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
por: Mahdi, Haider, et al.
Publicado: (2021)

Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer
por: Wilson, Andrew J., et al.
Publicado: (2021)

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance
por: Wang, Li‐Min, et al.
Publicado: (2023)

Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency
por: Schmitt, Antonin, et al.
Publicado: (2023)

GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC
por: Mabrouk, Nesrine, et al.
Publicado: (2023)

Impact of proton therapy on antitumor immune response
por: Mirjolet, Céline, et al.
Publicado: (2021)

Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
por: Cecchini, Michael, et al.
Publicado: (2023)

The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
por: Eliade, Marie, et al.
Publicado: (2016)

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro
por: Borchert, Sabrina, et al.
Publicado: (2019)

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer
por: Ledys, Fanny, et al.
Publicado: (2018)

The relative efficiency of homology-directed repair has distinct effects on proper anaphase chromosome separation
por: Laulier, Corentin, et al.
Publicado: (2011)

Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells
por: de Castro e Gloria, Helena, et al.
Publicado: (2021)

Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib
por: Roberts, Cai M., et al.
Publicado: (2023)

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

Micelle encapsulation zinc‐doped copper oxide nanocomposites reverse Olaparib resistance in ovarian cancer by disrupting homologous recombination repair
por: Yi, Jingyan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jkc31ncmf45bjvt3043l4ta789